首页> 外文期刊>The American Journal of Cardiology >Comparison of long-term outcome of off-pump coronary artery bypass grafting versus drug-eluting stents in triple-vessel coronary artery disease
【24h】

Comparison of long-term outcome of off-pump coronary artery bypass grafting versus drug-eluting stents in triple-vessel coronary artery disease

机译:体外循环冠状动脉搭桥术与药物洗脱支架治疗三支冠状动脉疾病的远期疗效比较

获取原文
获取原文并翻译 | 示例
           

摘要

After the introduction of drug-eluting stents (DESs), percutaneous coronary intervention with DESs has challenged coronary artery bypass grafting as the gold standard for the treatment of 3-vessel coronary artery disease. The purpose of this study was to compare the long-term clinical results between percutaneous coronary intervention with DESs and off-pump coronary artery bypass grafting (OPCAB) in 3-vessel coronary artery disease. Two hundred ninety propensity-score matched patients with 3-vessel coronary artery disease treated by DESs or OPCAB were included. Mean follow-up duration was 58.8 ± 11.5 months (2 to 73) and follow-up rate was 97.9%. Five-year survival rates were 94.8 ± 2.1% in the DES group and 96.5 ± 1.5% in the OPCAB group (p = 0.658). Five-year rates of freedom from major adverse cardiac and cerebrovascular event were 71.6 ± 4.1% in the DES group and 89.6 ± 2.5% in the OPCAB group (p <0.001). Freedom from nonfatal myocardial infarction and target vessel revascularization rates were the determining factors between the 2 groups (p = 0.018 and p <0.001, respectively). The OPCAB group showed better clinical outcomes compared to the DES group in 3-vessel coronary artery disease after 5-year follow-up. Freedom from major adverse cardiac and cerebrovascular event rate was significantly higher in the OPCAB group mainly because of the lower incidence of target vessel revascularization and nonfatal myocardial infarction. Longer follow-up with randomization will clarify our present conclusions.
机译:引入药物洗脱支架(DES)后,使用DESs进行经皮冠状动脉介入治疗已经挑战了冠状动脉搭桥术作为治疗3血管冠状动脉疾病的金标准。这项研究的目的是比较经皮冠状动脉介入治疗与3种冠状动脉疾病的经皮冠状动脉介入治疗与非体外循环冠状动脉搭桥术(OPCAB)的长期临床结果。包括DES或OPCAB治疗的290例倾向评分匹配的3支冠状动脉疾病患者。平均随访时间为58.8±11.5个月(2至73个月),随访率为97.9%。 DES组的五年生存率为94.8±2.1%,OPCAB组为96.5±1.5%(p = 0.658)。 DES组的5年免于发生严重心脏和脑血管不良事件的自由率是71.6±4.1%,OPCAB组是89.6±2.5%(p <0.001)。无致命性心肌梗死和靶血管血运重建率是两组之间的决定因素(分别为p = 0.018和p <0.001)。随访5年后,OPCAB组在3支冠状动脉疾病中的临床疗效优于DES组。 OPCAB组免于发生主要不良心脏和脑血管事件的发生率明显更高,这主要是由于目标血管血运重建和非致命性心肌梗塞的发生率较低。更长的随机随访将阐明我们目前的结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号